Sepsis‑associated acute kidney injury (SA‑AKI) is presented as a complex syndrome driven by interacting disturbances in inflammation, metabolism, microcirculation, mitochondrial function and programmed cell death. Rather than attributing renal injury to a single dominant pathway, the review argues for an integrated cell death network model in which multiple death programs operate heterogeneously and with extensive crosstalk. This reframing seeks to prioritize shared regulatory conditions that permit or amplify several death modalities, and to reorient therapeutic thinking away from single‑target inhibition toward reshaping upstream environments that enable multiple harmful processes.
The authors synthesize evidence that apoptosis, pyroptosis, ferroptosis, necroptosis and autophagy‑related responses do not act in isolation during SA‑AKI. Instead, these modalities form a network characterized by compensatory signaling and disease‑stage dependent regulation. The integrated view emphasizes that blocking one execution pathway may be insufficient if upstream drivers, amplifiers or permissive cellular states remain unaddressed. The review therefore organizes mechanistic evidence by shared nodes that influence multiple death programs.
A core set of upstream drivers and permissive states is described as creating the conditions in which multiple cell death pathways become active. Prominent among these are systemic and local inflammatory activation, immunometabolic stress and perturbations in cellular energetics. These upstream conditions can both initiate and sustain cross‑talk among death programs. The review highlights the importance of distinguishing driver mechanisms from downstream execution events when considering therapeutic interventions.
Amplifier mechanisms that intensify injury across death modalities receive focused attention. Examples include NF‑κB‑dependent inflammatory activation and inflammasome priming, which can both facilitate pyroptotic responses and augment other forms of programmed death. By identifying these shared amplifiers, the framework points toward interventions that might reduce the overall propensity for multiple death pathways to proceed, rather than selectively targeting a single terminal pathway.
Mitochondrial dysfunction is emphasized as a central permissive state that links metabolic collapse to several cell death programs. Related themes include redox‑iron imbalance and compromised autophagy/mitophagy, which impair organelle quality control and increase susceptibility to ferroptosis and other forms of cell death. The review underscores that restoring mitochondrial function and autophagic clearance may simultaneously mitigate multiple downstream execution mechanisms in SA‑AKI.
The review examines how diet‑related small molecules could influence the shared injury conditions that enable integrated cell death. Compounds are categorized into food‑derived phytochemicals, nutritional compounds, microbiota‑derived metabolites and ICU‑based antioxidant or vitamin regimens. The authors argue that the potential efficacy of these agents may rest less on selective inhibition of isolated death programs and more on their capacity to reshape upstream metabolic, redox and inflammatory environments that permit multiple death pathways to manifest.
Discussion in the review differentiates compound classes by likely mechanisms: phytochemicals and nutritional compounds may modulate redox balance, mitochondrial resilience and inflammatory signaling; microbiota‑derived metabolites could influence systemic immunometabolism; and antioxidant or vitamin regimens used in intensive care settings aim to correct oxidative deficits. The source emphasizes that active metabolites, compound bioavailability and in‑host transformations are critical determinants of any in vivo effect.
The authors identify several major translational challenges when moving diet‑related small molecules toward clinical testing in SA‑AKI. These include limited bioavailability of many phytochemicals, uncertainty about the identity and activity of in vivo metabolites, and altered pharmacokinetics in the septic patient. Additional barriers are disease‑stage specificity (timing of intervention relative to evolving injury), renal target exposure (achieving effective concentrations in kidney tissue) and inter‑patient heterogeneity that may obscure signals in clinical studies. The review notes that these obstacles complicate interpretation of preclinical findings and the design of robust clinical trials.
To address translational gaps, the review proposes an evaluation framework that explicitly considers exposure and patient endotypes. An exposure‑aware approach incorporates bioavailability, metabolite profiling and sepsis‑specific pharmacokinetics to ensure meaningful target engagement. An endotype‑guided strategy stratifies patients by dominant pathophysiologic features or molecular signatures, recognizing that SA‑AKI is heterogeneous and that interventions may only benefit subgroups with particular upstream permissive states. Together, these principles aim to improve the likelihood that diet‑related small molecules, if effective, will show replicable benefit in appropriately selected patients and time windows.
The review reframes SA‑AKI as a syndrome driven by an integrated and heterogeneous network of programmed cell death modalities underpinned by shared upstream drivers, amplifiers and permissive states. It highlights mitochondrial dysfunction, redox‑iron imbalance, NF‑κB activation, inflammasome priming and failures in autophagy/mitophagy as central shared nodes. Diet‑related small molecules are presented as multi‑target modulators that may exert benefit by altering these upstream environments rather than by selectively inhibiting single execution pathways. Significant translational barriers remain, and the authors recommend exposure‑aware and endotype‑guided study designs to more reliably test the clinical potential of these compounds in SA‑AKI.